NCT01551511View on ClinicalTrials.gov

Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Pancreatitis, ChronicAbdominal PainChronic Pain
Interventions
DRUG

Tetrahydrocannabinol

The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.

DRUG

Placebo

Identical step-up approach to the Namisol arm.

Trial Locations (1)

6500 HB

Radboud University Nijmegen Medical Centre, Nijmegen

All Listed Sponsors
collaborator

European Union

OTHER

lead

Radboud University Medical Center

OTHER

NCT01551511 - Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain | Biotech Hunter | Biotech Hunter